InnoCare Pharma
SEHK:9969 Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
AN
Consensus Narrative from 9 Analysts
Advancing Orelabrutinib And Autoimmune Therapies Will Open New Market Opportunities
Key Takeaways Orelabrutinib's market position and expansion are set to boost revenue, supported by ongoing clinical advancements and strategic approvals. Streamlined operations and strong cash reserves enhance financial stability and provide flexibility for pipeline growth and strategic initiatives.
View narrativeHK$8.73
FV
3.2% undervalued intrinsic discount36.63%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
2 days ago author updated this narrative